Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
4.41B | 4.24B | 3.70B | 3.39B | 2.99B | 2.67B | Gross Profit |
4.07B | 3.93B | 3.44B | 3.19B | 2.84B | 2.54B | EBIT |
175.53M | 61.37M | 620.52M | 579.44M | 585.78M | -240.29M | EBITDA |
406.83M | 408.16M | 919.43M | 599.64M | 630.20M | -178.24M | Net Income Common Stockholders |
21.27M | 32.62M | 597.60M | 340.66M | 948.58M | -295.70M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.41B | 2.16B | 3.66B | 3.24B | 2.35B | 1.80B | Total Assets |
5.75B | 5.44B | 6.78B | 5.84B | 4.93B | 3.56B | Total Debt |
43.12M | 43.54M | 38.29M | 44.64M | 34.27M | 34.86M | Net Debt |
-1.90B | -1.64B | -3.18B | -2.91B | -2.02B | -1.48B | Total Liabilities |
2.08B | 2.00B | 1.59B | 1.47B | 1.16B | 949.65M | Stockholders Equity |
3.67B | 3.45B | 5.19B | 4.37B | 3.77B | 2.61B |
Cash Flow | Free Cash Flow | ||||
288.81M | 249.07M | 449.00M | 892.11M | 568.48M | -311.98M | Operating Cash Flow |
382.59M | 335.34M | 496.49M | 969.94M | 749.49M | -124.60M | Investing Cash Flow |
231.73M | 157.52M | -207.68M | -78.54M | -207.70M | -269.00M | Financing Cash Flow |
-2.02B | -2.02B | -20.03M | -794.00K | 6.18M | 71.71M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $11.96B | 11.03 | 22.69% | ― | 25.11% | 46.46% | |
80 Outperform | $12.18B | 20.99 | 30.22% | ― | 24.49% | 244.87% | |
77 Outperform | $11.26B | 21.62 | 9.64% | ― | 17.99% | 152.10% | |
75 Outperform | $13.52B | 12.13 | 19.94% | ― | 19.85% | 21.16% | |
71 Outperform | $11.84B | 194.18 | 0.47% | ― | 17.13% | -88.78% | |
52 Neutral | $5.04B | 3.15 | -44.58% | 2.85% | 16.08% | -0.27% | |
52 Neutral | $9.49B | ― | 357.68% | ― | 10.69% | 34.71% |
On May 11, 2025, Incyte Corporation and Novartis Pharma AG reached a settlement agreement concerning a litigation over royalty payments related to JAKAFI sales in the United States. Incyte agreed to pay Novartis $280 million for disputed royalties and to reduce future royalty rates by 50% starting January 1, 2025, impacting the company’s financial statements for the quarter ending June 30, 2025.
The most recent analyst rating on (INCY) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.
Spark’s Take on INCY Stock
According to Spark, TipRanks’ AI Analyst, INCY is a Outperform.
Incyte’s overall stock score of 75 reflects its strong financial performance and a positive outlook from the recent earnings call, which highlighted significant revenue growth and successful product launches. These strengths are somewhat offset by the technical analysis indicating potential bearish trends and a high P/E ratio suggesting overvaluation. While the company is financially stable, improving profitability margins could further enhance its stock performance.
To see Spark’s full report on INCY stock, click here.